---
title: "Varegacestat (AL102) in Desmoid tumors: Tyrosine kinase inhibitors"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Tyrosine kinase inhibitors. Topics: NCCN placement of sorafenib, imatinib, and pazopanib as quoted in a payer policy; Guideline updates naming sorafenib a category 1 preferred regimen; Desmoid Tumor Working Group assessment of tyrosine kinase inhibitors; Sorafenib phase 3 trial: design and efficacy; 8 further topics. 12 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/tyrosine-kinase-inhibitors"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Tyrosine kinase inhibitors

<a id="heading-2.2.2.1.6"></a>

## 2.2.2.1.6 Tyrosine Kinase Inhibitors

<a id="topic-2.2.2.1.6-1"></a>

### NCCN placement of sorafenib, imatinib, and pazopanib as quoted in a payer policy

> “The National Comprehensive Cancer Network (NCCN) soft tissue sarcoma guidelines (version 1.2025 – May 2, 2025) recommend the following therapies as”
> “Ogsiveo (category 1), sorafenib (category 1), methotrexate and vinorelbine, methotrexate and vinblastine, imatinib, pazopanib, doxorubicin ± dacarbazine, and Doxil® (liposomal doxorubicin for intravenous injection) [except for Ogsiveo and sorafenib, all other agents listed are category 2A recommendations].”

Source: [Cigna nirogacestat coverage policy (2025)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_832_coveragepositioncriteria_oncology_ogsiveo_pa.pdf)

<a id="topic-2.2.2.1.6-2"></a>

### Guideline updates naming sorafenib a category 1 preferred regimen

> “After this analysis ended in August 2023 and the United States Food and Drug Administration (FDA) approval of nirogacestat, the NCCN Guidelines and DTWG guidelines were updated to include sorafenib and nirogacestat as Category 1, Preferred systemic regimens [14, 16, 18].”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.2.1.6-3"></a>

### Desmoid Tumor Working Group assessment of tyrosine kinase inhibitors

> “All three prospective, single-arm, phase II trials demonstrated activity of imatinib with high rates of disease stabilisation (60–80%) despite rather low response rates (6–19%) and with the expected well-known toxicity profile of imatinib.”
> “Imatinib should clearly not be the treatment of first choice if DT remission is intended.”
> “Sorafenib is an active agent and currently the best-studied TKI in DTs.”
> “Limitations of the study are the inclusion of patients with very modest increase in tumour size (10%), no central radiological review and no guidelines to assess symptoms severity suggesting that many patients included in this study would probably not have required an active treatment.”
> “Taken together, these findings show clear clinical benefit of TKIs in DT. The effect appears to be more pronounced with sorafenib and pazopanib compared to imatinib and likely achievable with even low dosages, limiting the potential adverse effects.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.1.6-4"></a>

### Sorafenib phase 3 trial: design and efficacy

> “In this double-blind, phase 3 trial, we randomly assigned 87 patients with progressive, symptomatic, or recurrent desmoid tumors to receive either sorafenib (400-mg tablet once daily) or matching placebo.”
> “With a median follow-up of 27.2 months, the 2-year progression-free survival rate was 81% (95% confidence interval [CI], 69 to 96) in the sorafenib group and 36% (95% CI, 22 to 57) in the placebo group (hazard ratio for progression or death, 0.13; 95% CI, 0.05 to 0.31; P<0.001). Before crossover, the objective response rate was 33% (95% CI, 20 to 48) in the sorafenib group and 20% (95% CI, 8 to 38) in the placebo group.”
> “The median time to an objective response among patients who had a response was 9.6 months (interquartile range, 6.6 to 16.7) in the sorafenib group and 13.3 months (interquartile range, 11.2 to 31.1) in the placebo group.”
> “On the basis of the predictable toxic-effects profile and substantial progression-free survival advantage conferred by sorafenib, the drug has antitumor activity as first-line therapy or as subsequent therapy for desmoid tumors.”

Source: [Gounder et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6447029/)

<a id="topic-2.2.2.1.6-5"></a>

### Sorafenib phase 3 trial: adverse events, dose modification, and discontinuation

> “Among patients who received sorafenib, the most frequently reported adverse events were grade 1 or 2 events of rash (73%), fatigue (67%), hypertension (55%), and diarrhea (51%).”
> “Dose interruptions occurred in 65% of the patients in the sorafenib group (32 of 49) and 34% of the patients in the placebo group (12 of 35), and dose reductions due to toxic effects occurred in 31% (15 of 49) and 11% (4 of 35), respectively.”
> “Adverse events led to a significantly higher rate of discontinuation of the trial regimen in the sorafenib group than in the placebo group (20% vs. no patients).”
> “Grade 3 adverse events that were attributed to the trial regimen by the investigators occurred in 29% of patients in the sorafenib group and 14% of patients in the placebo group. Grade 4 events that were associated with sorafenib included thrombocytopenia (2%) and anemia (2%).”

Source: [Gounder et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6447029/)

<a id="topic-2.2.2.1.6-6"></a>

### Pazopanib in the DESMOPAZ randomized phase 2 trial

> “DESMOPAZ was a non-comparative, randomised, open-label, phase 2 trial conducted at 12 centres from the French Sarcoma Group.”
> “Participants were randomly assigned (2:1) to oral pazopanib 800 mg per day for up to 1 year or to an intravenous regimen combining vinblastine (5 mg/m2 per dose) and methotrexate (30 mg/m2 per dose), administered weekly for 6 months and then every other week for 6 months.”
> “In the first 43 patients assessable for the primary endpoint in the pazopanib group, the proportion of patients who had not progressed at 6 months was 83·7% (95% CI 69·3-93·2).”
> “The most common grade 3 or 4 adverse events in the pazopanib group were hypertension (n=10, 21%) and diarrhoea (n=7, 15%)”
> “11 patients (23%) had at least one serious adverse event related to study treatment in the pazopanib group”

Source: [Toulmonde et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31331699/)

<a id="topic-2.2.2.1.6-7"></a>

### Imatinib in the German Interdisciplinary Sarcoma Group phase 2 trial

> “We initiated a phase II trial within the German Interdisciplinary Sarcoma Group (GISG) evaluating imatinib to induce progression arrest”
> “Thirty-eight patients (median age 44 years [range: 19-80]; 68% female; 90% Eastern Cooperative Oncology Group (ECOG) performance status 0) were treated with a daily dose of 800 mg imatinib planned over 2 years.”
> “The final analysis for the primary end-point in the evaluable patients of the full analysis set revealed a PAR6mo of 65%. Subsequent progression arrest rates at 9, 12, 15, 18, 21 and 24 months were 65%, 59%, 53%, 53%, 50% and 45%, respectively.”
> “Best reported response was seven partial responses at 21 months revealing an overall response rate of 19%.”
> “In general imatinib adverse events were mild to moderate.”

Source: [Kasper et al. (2017a)](https://pubmed.ncbi.nlm.nih.gov/28282612/)

<a id="topic-2.2.2.1.6-8"></a>

### Imatinib in a two-stage phase 2 study

> “Forty patients with unresectable and progressive symptomatic AF/DT were treated with imatinib (400 mg/day for 1 year) in a Simon's optimal two-stage phase II study”
> “The non-progression rates at 3, 6 and 12 months were, respectively, 91%, 80% and 67%. The 2-year progression-free and overall survival rates were 55% and 95%, respectively.”

Source: [Penel et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/20622000/)

<a id="topic-2.2.2.1.6-9"></a>

### Real-world sorafenib and pazopanib in an 11-institution retrospective cohort

> “Patients diagnosed with DTs and treated with sorafenib or pazopanib between 2011 and 2022 at 11 institutions were reviewed.”
> “142 patients with DT treated with sorafenib (n = 126, 88.7 %) or pazopanib (n = 16, 11.3 %) were analyzed.”
> “The overall response rate and the disease control rate were 26.0 % and 95.1 %, respectively.”
> “The 1-year and 2-year progression-free survival rates were 82 % and 80 %. Dose reductions were necessary in 34 (23.9 %) patients. Grade 3 or higher adverse events were reported in 36 (25.4 %) patients.”
> “Treatment discontinuation (n = 85, 59.9 %) was mainly for toxicity (n = 35, 45.9 %) or radiological or clinical progression (n = 30, 35.3 %).”

Source: [Noujaim et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38759389/)

<a id="topic-2.2.2.1.6-10"></a>

### Sorafenib discontinuation after response in the SORASTOP phase 2 study

> “The SORASTOP study reports long-term outcomes following planned sorafenib discontinuation in responding patients with extremity desmoid-type fibromatosis (DTF).”
> “In this prospective, single-arm phase 2 Simon's two-stage trial, adults with non-progressive, extremity DTF, ESAS pain < 2, after ≥ 12 months of sorafenib were enrolled.”
> “PFS at 12, 24 and 36 months were 90.8 %, 74.5 % and 74.5 % respectively; with median follow-up of 37 months.”

Source: [Singh et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41610807/)

<a id="topic-2.2.2.1.6-11"></a>

### Tyrosine kinase inhibitor use reported by study participants

> “Most participants (76%, 281/369) received systemic therapy (any line), including nonsteroidal anti-inflammatory drugs (NSAIDs; 40%, 112/281), tyrosine kinase inhibitors (32%, 91/281), chemotherapy (31%, 87/281), and hormone antagonists (17%, 47/281; Table 2).”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.2.1.6-12"></a>

### Funding status of tyrosine kinase inhibitors in England

> “Current treatment options include off-label chemotherapy, off-label tyrosine kinase inhibitors (TKIs) and surgery. The NHS England clinical lead noted that TKIs are not commissioned in the NHS in England for desmoid tumours, so would only be used through compassionate access or company-sponsored programmes.”
> “Sorafenib and pazopanib are both TKIs, and clinical expert advice to the EAG was that these could be considered similarly effective.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

Additional sources: [Kasper et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38900421/); [Agresta et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29384266/)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
